BeyondSpring Inc. (NASDAQ:BYSI) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price objective of $50.00 for the company and are anticipating that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given BeyondSpring an industry rank of 108 out of 265 based on the ratings given to related companies.

A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of BeyondSpring from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Rodman & Renshaw upped their price objective on shares of BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, July 14th. Finally, HC Wainwright set a $43.00 price objective on shares of BeyondSpring and gave the stock a “buy” rating in a research report on Wednesday, May 31st.

BeyondSpring (NASDAQ BYSI) traded up 4.28% during midday trading on Wednesday, reaching $40.00. The company’s stock had a trading volume of 1,458 shares. The stock’s 50 day moving average price is $39.34 and its 200-day moving average price is $30.30. The stock’s market cap is $868.28 million. BeyondSpring has a one year low of $16.55 and a one year high of $48.49.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with's FREE daily email newsletter.